Mohammed W. Badri: Are We Doing Enough to Prevent Life-Threatening Bleeds in Children?
Mohammed W. Badri, 6th year medical Student at University of Basrah – college of medicine, shared a post on LinkedIn:
“Are we doing enough to prevent life-threatening bleeds in children?
Last Tuesday at Basrah Speciality Children Hospital, I stood in front of my colleagues to present on a topic where a single mathematical miscalculation can change a child’s life: Clotting Factors Therapy.
Managing pediatric hemostasis isn’t just about giving a medication; it’s a high-stakes race against time.
When a child with severe Hemophilia comes in, every second counts. But the real challenge isn’t just treating the bleed—it’s what happens when the body fights back.
Here is what every healthcare professional and medical student needs to keep on their radar:
- The ‘Inhibitor’ Nightmare: The biggest barrier we face isn’t the deficiency itself, but when the patient’s immune system develops neutralizing antibodies (inhibitors) against Factor VIII or IX. It completely shatters the standard treatment plan.
- Precision Dosing over Guesswork: Target raises must be calculated dynamically (35-50% for standard bleeds, but strictly 100% for life-threatening ones like intracranial or GI bleeds).
- The Subcutaneous Shift: The traditional reliance on constant, painful IV pushes is shifting. Modern non-factor innovations like Emicizumab are completely redefining prophylaxis, especially for patients battling active inhibitors.
As medical providers, early recognition and switching from non-specific options to targeted factor replacement is what truly saves lives.
I have attached the full clinical presentation slides below. It breaks down the entire coagulation cascade, exact dosing formulas, and practical inhibitor management protocols.
If you are in the medical field, save this post for your next clinical rotation, and let’s discuss in the comments:
How is your center currently tackling the challenge of factor inhibitor development? ”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question